Axsome Therapeutics (AXSM) Stock May Trade At A Discount To Growth

Axsome Therapeutics has delivered a very large 5 year gain for shareholders, yet the recent pullback leaves a clear question for you as an investor. Is the current share price, at recent levels around US$161, really supported by the sales the business is generating today and those investors expect in the future?

• With the stock up about 296.3% over 5 years, long term holders have seen significant value created on paper. The key issue now is how that rise lines up with Axsome Therapeutics' underlying sales base.
• The business model relies heavily on turning its research pipeline and existing products into sustained revenue. This can materially affect how much investors are prepared to pay for each dollar of Axsome Therapeutics' sales.
• Your read on Axsome Therapeutics is one view; the desks covering it have another. See what analysts think Axsome Therapeutics's shares could be worth.

For investors, the debate is whether Axsome Therapeutics' current share price is properly aligned with what its sales performance alone can justify.

If you want a broader sense of what investors are currently paying for strong top line stories, line Axsome Therapeutics up against the companies in the 33 high quality undervalued stocks

Is Axsome Therapeutics a Bargain on Sales?

For a business like Axsome Therapeutics that is still working through losses, P/S is a cleaner way to see what investors are paying for its current revenue base. On this yardstick, the stock trades around 10.9x sales, which is more than double the wider Pharmaceuticals industry average of about 4.5x.

Set against closer peers, Axsome Therapeutics also prices at a premium, with its 10.9x multiple sitting above the group average near 9.9x. The fair multiple implied by its own profile, including factors like growth potential, profitability prospects and risk, points to a higher figure than where the shares trade today. On this framework, the current P/S suggests the stock is undervalued. Explore the numbers behind Axsome Therapeutics's P/S valuation.

The Axsome Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Axsome Therapeutics pick up where the P/S puzzle leaves off. They spell out which assumptions on Axsome Therapeutics' future growth, profit margins and earnings would need to hold for the shares to be worth materially more or less than today's level. Instead of a single multiple or model line, they set out the drivers behind each fair value view so you can compare those expectations with the results that actually arrive on the Community page.

One of the top community narratives on Axsome Therapeutics: 43% undervalued

"Diverse CNS product portfolio and late-stage pipeline position company to capitalize on global demand trends while reducing dependence on single products…"

Discover why this Narrative puts Axsome Therapeutics at 43% undervalued.

One more Axsome Therapeutics clue before you decide what to do next

There is one more angle to check before you put too much weight on today's price, which is how professional analysts currently see Axsome Therapeutics a few years down the road compared with where the shares trade now. Explore where analysts expect Axsome Therapeutics to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com